Ultragenyx Pharmaceutical stock is under pressure after a multi year slide in returns, yet current market multiples still screen as expensive and the broader valuation checks send a mixed message. With fresh clinical setbacks alongside some positive data elsewhere in the pipeline, investors face conflicting signals about what the current price really reflects.
-
Over the past 5 years the share price has fallen about 85%, which points to a sharp reset in market expectations for Ultragenyx Pharmaceutical.
-
The failure of the Phase 3 Aspire study in Angelman syndrome may weigh on expectations for future cash generation, while ongoing work on gene therapies such as GENGLYCOS can still support sentiment if the commercial path proves viable.
-
The stock currently looks overvalued on market multiples and the broader valuation checks give a mixed picture rather than a clear bargain or clear overvaluation. The value score of 4 out of 6 sits in the middle of the range.
The stock's next move may depend on whether Ultragenyx Pharmaceutical can justify this mixed valuation profile through its clinical outcomes and eventual commercial performance.
Spot opportunities beyond Ultragenyx Pharmaceutical's recent slide by reviewing a hand picked list of beaten down biotechs and quality healthcare stocks in 47 high quality undervalued stocks .
Does Ultragenyx Pharmaceutical Look Pricey on Sales?
P/S is a useful lens for Ultragenyx Pharmaceutical because revenue is more stable than earnings while the company invests heavily in its pipeline. On this measure, Ultragenyx trades on a P/S of about 2.1x, compared with roughly 13.1x for the broader biotechs industry and around 6.5x for closer peers. That places the stock well below both benchmarks on simple sales multiples.
The fair P/S ratio for Ultragenyx, which adjusts for its risk profile and business characteristics, is estimated at about 1.8x. The current 2.1x level sits modestly above that tailored fair ratio. As a result, despite the discount to sector and peer averages, the stock screens as overvalued on this specific framework. The recent Angelman trial setback and cost cutting plans have not pushed the P/S multiple down to a level that this model would flag as a clear discount.
Overall, Ultragenyx Pharmaceutical appears overvalued on the preferred P/S multiple, even though it trades below typical biotech sales multiples.
See what the numbers say about this price — find out in our valuation breakdown.
The Ultragenyx Pharmaceutical Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Ultragenyx Pharmaceutical extend the valuation puzzle by explaining which assumptions on growth, margins and future earnings would need to hold for the stock to be worth materially more or materially less than it is today. Each narrative connects a fair value estimate to a specific storyline about Ultragenyx Pharmaceutical's potential catalysts and key risks, allowing you to track over time which version of events appears closer to reality on the Community page.
One of the top community narratives on Ultragenyx Pharmaceutical: 41% undervalued
"Ultragenyx has phenomenal science, but its commercial execution is a cash-incinerating treadmill..."
Read one of the top narratives on Ultragenyx Pharmaceutical
Do you think there's more to the story for Ultragenyx Pharmaceutical? Head over to our Community to see what others are saying!
The Bottom Line
Ultragenyx Pharmaceutical currently screens as overvalued on the preferred P/S framework, even though it trades below broader biotech sales multiples. The mixed value score underlines that the checks do not yet point to a clear mispricing in either direction. For you, the key question is whether the existing pipeline can deliver enough durable revenue and margin progress to make the current premium to its tailored fair ratio feel justified. That expectation around future commercial execution, more than any single trial outcome, is what separates the bull and bear cases from here.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include RARE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
